Mirion Technologies (MIR – Research Report), the Industrials sector company, was revisited by a Wall Street analyst yesterday. Analyst Andrew Kaplowitz from Citi maintained a Buy rating on the stock and has a $20.00 price target.
Andrew Kaplowitz has given his Buy rating due to a combination of factors that highlight Mirion Technologies’ promising growth trajectory and strategic positioning. After visiting the company’s Medical headquarters, he observed that Mirion is well on track to achieve its long-term goals of organic growth and margin improvement, which are crucial for reaching a 30% company-wide adjusted EBITDA margin by 2028. The company’s strategy in the Medical division, focusing on integrating software with hardware and emphasizing independent quality assurance, is expected to drive performance improvements.
Additionally, Mirion Technologies is experiencing momentum as a leading provider of quality assurance support in radiation therapy and nuclear medicine. The introduction of new technologies like Instadose and the increasing adoption of SaaS-based products are seen as potential growth catalysts. Furthermore, the company’s margin opportunities appear underappreciated, with higher-margin software and services rising as a percentage of sales. The favorable acquisition landscape and manageable tariff-related impacts further support the positive outlook for Mirion Technologies.
In another report released on February 18, Goldman Sachs also reiterated a Buy rating on the stock with a $21.00 price target.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MIR in relation to earlier this year.